A research team headed by Dr. Chandima Jeewandara from University of Sri Jayewardenepura today announced the findings of their research on effectiveness of Sinopharm Vaccine in generating antibody response against COVID 19. According to the results the vaccine has been able to produce antibody responses in 95% of the vaccinees. The research carried out at The Allergy, Immunology and Cell Biology Unit, Department of Immunology Molecular and Molecular Medicine of University of Sri Jayawardenapura investigated immune responses to the Sinopharm vaccine among vaccinated Sri Lankans. The research team included researchers from University of Oxford including Prof. Graham Ogg and Prof. Alain Townsend. The funding for this study was provided by the World Health Organization, UK Medical Research Council and the Foreign and Commonwealth Office and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China.
According to the research findings the vaccine is very much effective in generating antibody responses against both alpha and delta variants of the COVID 19 virus. The research also have found that the antibody response in individuals over 60 years are significantly lower than younger individuals. The seroconversion rate in individuals >60 years was 93.3% and in those who were 20 to 39 years the response was at 98.9%.
The full preprint highlighting the results are available here: Antibody and T cell responses to Sinopharm/BBIBP-CorV in naive and previously infected individuals in Sri Lanka | medRxiv
Featured image – Pan American Health Organization PAHO – Flickr
